Wugen

Our pivotal Phase 2 T-RRex trial of WU-CART-007 is officially underway! With previous data showing a composite complete remission rate of 73% and 91% overall response rate, WU-CART-007 has the potential to redefine care for patients with relapsed or refractory T-ALL/LBL.   Stay tuned as we continue our work to deliver a transformative off-the-shelf CAR-T therapy. More details here: https://bit.ly/4inhOBk

Today we announced we dosed the first patients in the pivotal Phase 2 T-RRex Study of WU-CART-007, our off-the-shelf, allogeneic CAR-T therapy targeting CD7+ relapsed or refractory T-ALL/LBL.   With RMAT, Fast Track, Orphan Drug, and Rare Pediatric Disease designations, WU-CART-007 is designed to bring a much-needed new option to patients facing limited treatment alternatives.   Learn more about our pivotal Phase 2 T-RRex trial: https://bit.ly/4inhOBk

We are thrilled to announce that Dr. Jim Faulkner has joined Wugen as Chief Technical officer. Jim brings with him a specialized skillset and innovative technology experience that includes working with and advising companies on diverse aspects of gene and cell therapy development. We continue to focus on the launch of our pivotal Phase 2 trial for WU-CART-007, the first CD7-targeted allogeneic CAR-T cell therapy, during what will be a year of significant momentum for the company. Jim will be a great asset as we continue that progress. https://bit.ly/4ib7rzQ

Biotech News: Wugen to initiate pivotal trial for WU-CART-007 and present data updates at American Society of Hematology Annual Meeting 2024. These data support the start of first pivotal phase 2 trial for an off-the-shelf, allogeneic CD7-targeted CAR-T cell therapy in pediatric and adult patients. Maturing evidence, including the updates being presented this week, suggest WU-CART-007 has potential to improve current standard of care for patients with T-ALL/LBL malignancies associated with high rates of relapse and mortality, including the very young. Read today's news: https://bit.ly/3ZgWzIW #ASH24

With over two decades of experience in clinical development and regulatory leadership, we’re pleased to announce that Dr. Cherry T. Thomas, M.D., has joined Wugen as our Chief Medical Officer. Dr. Thomas brings invaluable expertise as we advance our pivotal Phase 2 trial of WU-CART-007, our CD7-targeted CAR-T therapy for T cell malignancies, aiming to bring new hope to patients with limited treatment options. https://bit.ly/3O4AN5Z

Biotech News: Wugen announces the company will initiate our pivotal Phase 2 trial for WU-CART-007 in the first quarter of 2025. This off-the-shelf, allogeneic CD7-targeted CAR-T cell therapy is designed to address the unmet needs of patients with relapsed or refractory T cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic lymphoma (T-LBL). After 20 years with limited advancements for relapsed or refractory T-ALL/LBL, we believe off-the-shelf allogeneic CD7-targeted CAR-T cell therapies may offer hope and innovation. Read today's news: https://bit.ly/40CUgSR

#EHA2024 Data: Wugen presents positive Phase 2 results for WU-CART-007. During today’s oral presentation at the European Hematology Association (EHA) 2024 Hybrid Congress, researchers shared positive Phase 2 results for our investigational allogeneic, off-the-shelf anti-CD7 CAR-T therapy in patients with relapsed/refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL). Learn more about what these WU-CART-007 findings could mean for patients with hard-to-treat blood cancers: https://bit.ly/4aXdRi4 #celltherapy #research #biotechnology #WashU

BIOTECH NEWS: Wugen announced RMAT and PRIME designations to accelerate regulatory reviews for its investigational, off-the-shelf allogeneic CAR-T cell therapy, WU-CART-007, in the U.S and E.U. These designations follow FDA and EMA review of Wugen studies, including its global Phase 1/2 study. The newest Phase 2 data will be presented at European Hematology Association (EHA)'s 2024 meeting in June. Learn more about todays’ news and WU-CART-007: https://bit.ly/3wPuRIX #EHA2024 #cancer #celltherapy

BIOTECH NEWS: Wugen announced RMAT and PRIME designations to accelerate regulatory reviews for its investigational, off-the-shelf allogeneic CAR-T cell therapy, WU-CART-007, in the U.S and E.U. These designations follow FDA and EMA review of Wugen studies, including its global Phase 1/2 study. The newest Phase 2 data will be presented at European Hematology Association (EHA)'s 2024 meeting in June. Learn more about todays’ news and WU-CART-007: https://bit.ly/3wPuRIX #EHA2024 #cancer #celltherapy

We’re hiring! Wugen is seeking an exceptional and highly motivated candidate to join our growing QA team based in St. Louis, MO or San Diego, CA. The person in this role will be responsible for helping maintain Wugen's quality systems through electronic document management. Learn more: https://lnkd.in/df2XrytM